Q1 2019 Results

26 April 2019 07:00 BST

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. In Oncology, Tagrisso, Imfinziand Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta and Fasenra also grew strongly. Emerging Markets, our largest sales region, delivered an outstanding performance with a 22% growth rate; all of its sub-regions grew strongly, including China at 28%.

Our Core Operating Profit almost doubled, demonstrating strong operating-margin improvement. Together with this encouraging financial start to the year, our highly-productive and sustainable pipeline continued to deliver, notably with a regulatory approval for Lynparzain the EU for the treatment of metastatic breast cancer and approvals of Farxigain type-1 diabetes. The recently-announced collaboration with Daiichi Sankyo also broadened an exciting Oncology portfolio with a potentially-transformative cancer treatment that could benefit patients around the world. We appreciate the support from our shareholders in realising this exceptional opportunity.”



Q1 2019 Results announcement
Q1 2019 Results presentation
Q1 2019 Results clinical trials appendix

Adrian Kemp
Company Secretary
AstraZeneca PLC


  • Corporate and financial